RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viracta Therapeutics (NASDAQ:VIRX), maintaining a $7 price target.
August 15, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Viracta Therapeutics, maintaining a $7 price target.
The reiteration of an Outperform rating by RBC Capital indicates a positive outlook for Viracta Therapeutics. The maintained price target of $7 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100